Purdue University-affiliated biotechnology company recognized as Most Fundable Companies
OmniVis, a Purdue University-affiliated biotechnology company focused on the speed, accuracy and economics of pathogen detection, has been named to the fifth annual Most Fundable Companies list from Pepperdine University’s Graziadio Business School.
OmniVis makes iSpyDx hand-held devices that rapidly detect pathogens in food, water and plant samples. The devices perform to laboratory method standards but do not require special equipment or training.
CEO Katherine Clayton, who earned her PhD in mechanical engineering from Purdue, leads the company. Other co-founders are Purdue researchers Tamara Kinzer-Ursem, associate head for academic programs and the Marta E. Gross Associate Professor of Biomedical Engineering, Weldon School of Biomedical Engineering; Jacqueline Linnes, the Marta E. Gross Associate Professor of Biomedical Engineering, Weldon School of Biomedical Engineering, and director of the College of Engineering Honors Program; and Steven T. Wereley, professor of mechanical engineering, School of Mechanical Engineering.
“The Most Fundable Companies process involved six months of due diligence on OmniVis, providing even further confidence behind everything we are doing at the company,” Clayton said. “By winning the Most Fundable Companies, we were able to extend our network by meeting great entrepreneurs and investors as well as those excited about entrepreneurship. We can’t wait for what comes next.”
Linnes said the technology’s core platform is disease-agnostic and has the ability to detect a variety of DNA and RNA targets.
“When paired with the right sample preparation and primers to amplify nucleic acids, the platform can detect pathogens from food, water and agricultural products, as well as those causing human diseases,” Linnes said. “We have demonstrated the detection of cholera from water samples and malaria, SARS-CoV-2 and HIV from human saliva and blood samples.”
Kinzer-Ursem said the iSpyDx device can be operated without specialized knowledge from the beginning of the detection process to the end.
“We’ve tested the device with a number of domestic and international partners,” Kinzer-Ursem said. “Users with and without technical training are able to use the device.”
Wereley said it is critical to bring university research and innovation to the marketplace. He said there are several options, including launching a company with a recent graduate to run it.
“The benefits of the small company approach are the close relationship between the company and the university researchers, which allows transferral of not just concepts but typically undisclosed know-how from the university to the small company,” Wereley said. “Also, companies have access to different funding streams, including federal SBIR and STTR grants, investors and more that can support research activities at the university.”